Investor profile for Sofinnova Crossover II (€725M final close, 2026): stage-based planning range, investment stages, sector focus, portfolio companies, sources, and verification status. Part of the Venture Capital Tracker directory.

VC fund profile · evidence-aware directory data

Sofinnova Crossover II (€725M final close, 2026) stages, portfolio and investment profile

Sofinnova Partners' second life-sciences crossover fund reached a €725M FINAL close announced November 16, 2026. It aims to back about 15 clinical-stage biopharma and medtech companies primarily in Europe, with selective global deals; Hemab, CellCentric and Neurent Medical are named portfolio companies. EIF's 2024 report records a €250M signature associated with the vehicle.

Exact investor check sizes, individual LP terms and the legal closing date are undisclosed.

Keep track of Sofinnova Crossover II (€725M final close, 2026)

Save this profile to your VCT watchlist for a quick return.

View watchlist

Stage-based planning range

$100K–$1M

This is a planning range inferred from stage coverage, not a firm-disclosed check size.

Methodology: Stage bucket inferred from the rounds a fund leads or invests in.

No firm-specific check-size disclosure is recorded.

Source link not recorded Confidence: 25% Verified: November 16, 2026 View methodology

Investment stages

Leads: Not recorded

Participates: Not recorded

Sector focus

Not recorded

Geography

Paris, France; European and selective global mandate

Founded Not recorded

Fund size / AUM

Not recorded

A separate fund-size evidence record is not yet available.

Portfolio in our directory

None yet

Linked startup profiles

Recent tracked investment

Not recorded

No dated round explicitly links this fund.

Rounds they lead

Rounds they invest

Last verified: 2026-11-16. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.